Royalty Pharma plc (NASDAQ: RPRX) is -5.91% lower on its value in year-to-date trading and has touched a low of $25.10 and a high of $31.66 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RPRX stock was last observed hovering at around $26.40 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $26.43, the stock is -0.29% and -3.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.46 million and changing 0.11% at the moment leaves the stock -5.65% off its SMA200. RPRX registered -2.76% loss for a year compared to 6-month gain of -0.71%. The firm has a 50-day simple moving average (SMA 50) of $27.2994 and a 200-day simple moving average (SMA200) of $28.01215.
The stock witnessed a -3.12% loss in the last 1 month and extending the period to 3 months gives it a -6.97%, and is 2.84% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.72% over the week and 2.06% over the month.
Royalty Pharma plc (RPRX) has around 89 employees, a market worth around $15.59B and $2.27B in sales. Current P/E ratio is 10.34 and Fwd P/E is 6.03. Profit margin for the company is 50.52%. Distance from 52-week low is 5.30% and -16.51% from its 52-week high. The company has generated returns on investments over the last 12 months (8.49%).
with sales reaching $622.43M over the same period.The EPS is expected to shrink by -11.36% this year, but quarterly earnings will post 12.66% year-over-year. Quarterly sales are estimated to grow 4.44% in year-over-year returns.
Royalty Pharma plc (RPRX) Top Institutional Holders
639.0 institutions hold shares in Royalty Pharma plc (RPRX), with institutional investors hold 83.79% of the company’s shares. The shares outstanding are 446.69M, and float is at 379.02M with Short Float at 3.84%. Institutions hold 72.76% of the Float.
The top institutional shareholder in the company is MORGAN STANLEY with over 44.13 million shares valued at $1.16 billion. The investor’s holdings represent 9.8375% of the RPRX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 38.02 million shares valued at $1.0 billion to account for 8.4754 of the shares outstanding. The other top investors are FMR LLC which holds 27.89 million shares representing 6.2161% and valued at over $735.37 million, while BLACKROCK INC. holds 5.1307 of the shares totaling 23.02 million with a market value of $606.97 million.
Royalty Pharma plc (RPRX) Insider Activity
The most recent transaction is an insider sale by RIGGS RORY B , the company’s Director. SEC filings show that RIGGS RORY B sold 235,200 shares of the company’s common stock on Jan 02 ’24 at a price of $28.52 per share for a total of $6.71 million. Following the sale, the insider now owns 0.25 million shares.
Royalty Pharma plc disclosed in a document filed with the SEC on Jan 03 ’24 that RIGGS RORY B (Director) sold a total of 199,098 shares of the company’s common stock. The trade occurred on Jan 03 ’24 and was made at $27.79 per share for $5.53 million. Following the transaction, the insider now directly holds 55801.0 shares of the RPRX stock.
Still, SEC filings show that on Jan 04 ’24, RIGGS RORY B (Director) disposed off 35,702 shares at an average price of $27.55 for $0.98 million. The insider now directly holds 20,099 shares of Royalty Pharma plc (RPRX).
